Gilead Sciences agreed to a $40 million settlement in June 2024 to resolve approximately 2,600 federal claims from patients who alleged they developed kidney disease and bone density loss from TDF-based HIV medications, including Truvada. Under this settlement, plaintiffs receive an average payout of approximately $12,500 each””a figure that many legal observers consider modest given the severity of the alleged injuries. For example, a plaintiff who developed osteoporosis requiring ongoing treatment and lifestyle modifications would receive the same baseline amount as someone with less severe bone thinning, though individual payouts may vary based on case specifics.
However, this federal settlement represents only a fraction of the broader litigation. More than 26,000 plaintiffs have filed lawsuits against Gilead across multiple states, meaning approximately 25,000 cases remain active in California, Missouri, and other jurisdictions. The company has maintained that the settlement represents no admission of liability or wrongdoing, stating it agreed to the terms “to avoid the cost and distraction of litigating these cases.” This article examines the current state of the Truvada bone loss litigation, what plaintiffs can realistically expect from settlements, the timeline for upcoming bellwether trials, and how these cases differ from Gilead’s separate government patent dispute resolved in January 2025.
Table of Contents
- What Does the Truvada Bone Loss Settlement Actually Pay Plaintiffs?
- Why Thousands of Truvada Cases Remain Unresolved
- California Supreme Court Case Could Reshape All Truvada Litigation
- Bellwether Trials Set to Test Both Sides’ Cases
- Understanding What the Truvada Lawsuits Actually Claim
- Gilead’s Separate Government Settlement Is Unrelated to Injury Claims
- What Comes Next for Truvada Litigation in 2026
- Conclusion
What Does the Truvada Bone Loss Settlement Actually Pay Plaintiffs?
The June 2024 federal settlement establishes a payout structure that averages $12,500 per plaintiff across the 2,600 covered claims. This amount reflects the total $40 million fund divided among participants, though actual individual payments may differ based on injury severity, medical documentation, and other case-specific factors. The settlement required at least 98 percent of eligible plaintiffs to opt in for the agreement to proceed””a high threshold that underscores how mass tort settlements depend on near-universal participation to function. To put this figure in perspective, $12,500 represents a fraction of what many bone injury plaintiffs face in medical expenses alone.
Treatments for osteoporosis and bone density loss often include bisphosphonate medications, regular DEXA scans, and in severe cases, surgeries for fractures. A single hip fracture surgery can cost $30,000 to $50,000 or more. This disparity between settlement amounts and actual damages explains why many plaintiffs and their attorneys view the federal settlement as a starting point rather than a final resolution. The settlement also carries an important limitation: it covers only federal claims consolidated in multidistrict litigation. Plaintiffs whose cases were filed in state courts””the vast majority of the 26,000 total””are not bound by these terms and may pursue their claims through trial or separate settlement negotiations.
Why Thousands of Truvada Cases Remain Unresolved
Despite the 2024 federal settlement, approximately 25,000 plaintiffs continue pursuing claims against Gilead in state courts across California, Delaware, Florida, Missouri, and New York. California hosts the largest concentration of these cases, which is significant because California state court procedures and jury pools may produce different outcomes than federal litigation. The central allegation uniting these cases is that Gilead knew its TDF-based drugs””including Truvada, Atripla, and Stribild””caused kidney damage and bone density loss, yet deliberately delayed releasing a safer alternative formulation called TAF (tenofovir alafenamide). Plaintiffs argue Gilead prioritized profits from TDF drugs while patients suffered preventable harm.
Internal company documents and the timeline of drug development form key evidence in these claims. However, proving these allegations at trial presents challenges. Gilead disputes that it withheld safer medication and contests the scientific claims about TDF’s relative risks. Plaintiffs must also establish that their specific injuries resulted from TDF rather than HIV itself or other factors””a medical causation question that requires expert testimony and thorough documentation. Cases with incomplete medical records or gaps in treatment history face steeper obstacles.
California Supreme Court Case Could Reshape All Truvada Litigation
A pending California Supreme Court case represents perhaps the most consequential development in the Truvada litigation landscape. Gilead’s reply brief was due in January 2026, with oral arguments expected in the first half of 2026. The court typically issues decisions within 90 days of oral argument, meaning a ruling could come by mid-2026. The outcome of this case could fundamentally alter how the remaining 25,000 claims proceed.
A ruling favorable to plaintiffs might strengthen settlement leverage across all pending cases, potentially leading to larger payouts than the $12,500 federal average. Conversely, a decision favoring Gilead could narrow the legal theories available to plaintiffs or limit recoverable damages. For example, if the California Supreme Court rules that plaintiffs can pursue claims based on Gilead’s alleged delay in releasing TAF, this precedent would apply to the thousands of California state court cases and likely influence litigation strategy nationwide. Attorneys representing Truvada plaintiffs are closely monitoring this proceeding as a bellwether for the entire litigation’s trajectory.
Bellwether Trials Set to Test Both Sides’ Cases
Bellwether trials scheduled for late 2025 through early 2026 in California state courts will serve as test cases to guide future settlement negotiations. These trials select representative cases from the larger pool to proceed to verdict, allowing both sides to gauge how juries respond to the evidence and arguments. The bellwether process presents a calculated risk for each party. For plaintiffs, a strong verdict could pressure Gilead toward more generous settlement terms across the remaining cases.
The $12,500 federal average might look very different if a bellwether jury awards millions to an individual plaintiff with severe bone injuries. For Gilead, defense verdicts would strengthen its negotiating position and potentially discourage plaintiffs from rejecting settlement offers. The tradeoff for plaintiffs considering whether to wait for bellwether outcomes versus settling now involves time, uncertainty, and financial need. Those with pressing medical expenses or other financial pressures may prefer certain””if modest””settlement payments over the possibility of larger awards years down the road. Plaintiffs with severe, well-documented injuries and the resources to wait may benefit from seeing how bellwether trials unfold before making decisions.
Understanding What the Truvada Lawsuits Actually Claim
The bone loss lawsuits against Gilead rest on specific allegations that plaintiffs must prove to recover damages. The core claim involves three connected assertions: TDF-based drugs caused kidney disease, kidney failure, bone density loss, and bone fractures; Gilead knew about these risks; and the company delayed releasing a safer alternative drug while continuing to profit from TDF formulations. A critical limitation in these cases involves distinguishing drug-caused injuries from conditions that might have developed regardless of medication. HIV infection itself can affect bone health, and many Truvada users have other risk factors for osteoporosis.
Plaintiffs must present medical evidence””typically through expert witnesses””establishing that TDF specifically caused their bone loss rather than other factors. Potential plaintiffs should understand that not everyone who took Truvada and experienced bone problems has a viable lawsuit. Cases require documented bone density loss or kidney damage, evidence linking the timing of drug use to symptom onset, and typically medical records showing the condition was unexpected given the patient’s age and health profile. An 80-year-old plaintiff with multiple osteoporosis risk factors faces different evidentiary challenges than a 35-year-old who developed significant bone loss shortly after starting TDF therapy.
Gilead’s Separate Government Settlement Is Unrelated to Injury Claims
On January 15, 2025, Gilead reached a final settlement with the U.S. Department of Justice and Department of Health and Human Services concluding a five-year patent dispute over Truvada and Descovy for PrEP use.
This resolution is entirely separate from the bone loss and kidney injury lawsuits and should not be confused with compensation for harmed patients. The government dispute centered on patent rights and licensing issues related to pre-exposure prophylaxis (PrEP) applications””essentially, a disagreement about intellectual property rather than product safety. For example, a plaintiff with bone loss injuries receives no benefit from this DOJ settlement, as it addressed legal questions between Gilead and federal agencies rather than individual patient harm.
What Comes Next for Truvada Litigation in 2026
The first half of 2026 will likely prove pivotal for the Truvada litigation. The California Supreme Court oral argument and subsequent decision, combined with bellwether trial outcomes, should provide clearer signals about whether Gilead will pursue broader settlements and at what amounts.
Plaintiffs currently in the litigation face continued waiting, but those with qualifying injuries who have not yet filed should consult attorneys about applicable statutes of limitations. State filing deadlines vary, and delays could forfeit otherwise valid claims. The litigation’s trajectory suggests that resolution””whether through settlement or trial””remains years away for most plaintiffs, requiring patience and realistic expectations about both timing and potential compensation.
Conclusion
The $40 million Truvada bone loss settlement in June 2024 resolved approximately 2,600 federal claims at an average of $12,500 per plaintiff, but this represents less than 10 percent of the total litigation. More than 25,000 cases continue in state courts, with bellwether trials and a California Supreme Court decision expected to shape the litigation’s future direction through 2026.
Plaintiffs considering their options should weigh the certainty of available settlements against the possibility of larger awards following bellwether verdicts. Those who have not yet filed claims should promptly consult with qualified attorneys to assess their cases and ensure they meet applicable deadlines. The litigation continues to evolve, and significant developments are expected in the coming months.